What is it about?
Despite advances in lung cancer treatment, most lung cancers are diagnosed at an advanced stage. Expression of microRNA10b (miR-10b) and fibrinolytic activity, as reflected by soluble urokinase-type plasminogen activator receptor (suPAR) and plasminogen activator inhibitor 1 (PAI-1), are promising biomarker candidates.
Featured Image
Photo by Robina Weermeijer on Unsplash
Why is it important?
We assess the expression of miR-10b, and serum levels of suPAR and PAI-1 in advanced stage non-small cell lung cancer (NSCLC) patients, and their correlation with progression, treatment response and prognosis.
Perspectives
I hope that through this research, we can gain insights into the use of biomarkers in non-small cell lung cancer (NSCLC) as predictors of cancer progression, treatment response, and prognosis.
Frederica Jovianti
Dharmais National Cancer Hospital, Jakarta, Indonesia
Read the Original
This page is a summary of: Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response, Cancer Biomarkers, February 2024, IOS Press,
DOI: 10.3233/cbm-220222.
You can read the full text:
Contributors
The following have contributed to this page
